Pharmacometrics · model-informed drug development

Find the faster path through drug development.

We identify where a model could save your program time and money: replace a study, resize a trial, support the dose or bring a decision forward. Then we build the models and deliver the evidence, documented to submission standard, at a fixed price and on a guaranteed date.

Program Scan · PMX-101
Small molecule · oncologyEnd of Phase 1
  1. ReduceMay replace a dedicated QT studyconcentration-QTc on intensive ECGs from Phase 1 dose escalation
  2. ReduceMay replace 2 of 4 planned DDI studiesPBPK verified against the strong CYP3A4 inhibitor study
  3. ImprovePhase 2 doses to compare, chosen from exposurepopulation PK and exposure-response, not only the MTD
  4. BenchmarkGo/no-go bar set before Phase 2 startsmodel-based meta-analysis against standard of care
  5. AcceleratePIP and iPSP ready on time, off the critical pathadult population PK scaled to children (size and maturation)
5 opportunities · up to 3 studies may not need to run

Example scan, fictional compound

48 h
Fixed proposal after the call
≤ 4 wk
From a clean dataset to the report
50%
Below a comparable CRO scope, on average
GxP
Computing environment, submission-ready deliverables
  • Population PK
  • PK/PD
  • Exposure-response
  • PBPK
  • IVIVC
  • NCA
  • Concentration-QTc
  • Virtual bioequivalence
  • Clinical trial simulation
  • Model-based meta-analysis
  • Pediatric extrapolation
  • First-in-human dose
  • Dose optimization

Most programs buy modeling one study at a time. We start from the whole program and find where a model could replace, resize or speed up a study.

  • Nonclinical and translational data
  • Clinical PK, PD and safety
  • Development plan and target product profile
  • Literature and competitor results
  • Regulatory history and agency feedback
pmxstudio One model-informed strategy for the asset
  • Decisions on dose, design and go/no-go
  • Studies replaced, reduced or resized
  • The asset benchmarked against its competitors
  • Evidence documented to submission standard, ready for the agency meeting
Behind every scan

A proprietary evidence system

Every scan runs on a system we built in-house. It reads your program's own data alongside the scientific literature, the agencies' guidances and years of public regulatory decisions, approvals and rejections alike. Each opportunity is weighed against what reviewers have actually accepted and questioned, not only against what a method can do.

  • Your programNonclinical and clinical data, development plan, target product profile
  • Scientific literaturePublished models, clinical results and competitor trials
  • Agency guidanceFDA, EMA and ICH guidances and their precedents
  • Regulatory decisionsYears of approvals, reviews and rejections

Four ways a model changes a program

Every opportunity we find falls under one of them. Most programs have several, at every stage.

Accelerate

Reach the next decision sooner

A first-in-human dose and escalation set from translational modeling, a Phase 2 dose chosen from exposure, a pediatric plan written while Phase 2 runs.

Reduce

Run fewer, smaller studies

Concentration-QTc in place of a thorough QT study, PBPK in place of some DDI studies, virtual bioequivalence to size a BE trial and, in specific cases, support a waiver, sparse sampling in place of rich.

Improve

Choose a dose and design you can defend

Exposure-response for efficacy and safety, trial simulation to test the design before you pay for it, covariate effects turned into dose adjustments.

Benchmark

Know where the asset stands

Model-based meta-analysis against standard of care and competitors, the effect needed to differentiate, and an independent read on the data before licensing or investment.

Featured application · Oncology · FDA Project Optimus

Dose optimization, built on exposure-response

FDA's 2024 oncology dosage guidance moves development away from taking the maximum tolerated dose into the registration trial by default. Sponsors are expected to compare dosages, with population PK, exposure-response and model-informed approaches among the tools to select them. It is a clear case of what a model-based strategy changes in a program: the dosages carried forward, the design of the dose-comparison trial, and the strength of the dosage justification presented to FDA.

  1. Dose findingPopulation PK and early exposure-response for safety and activity, updated as each cohort reads out, to select the dosages worth comparing.
  2. Dose comparisonThe randomized dose-comparison trial evaluated by simulation before it starts: dosages, arms and sample size.
  3. FDA meetings and the applicationExposure-response for efficacy and safety, and the dosage justification for the end-of-phase meetings and the filing.

Models support the randomized comparison of dosages that FDA recommends; they do not replace it. Source: FDA guidance for industry, Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases, August 2024.

The engagement

From the first scan to the agency meeting, one team

You can start at any step. Most clients start with the Program Scan, steps 1 and 2, because it shows where the time and money are.

01

Scout the program

We read your development plan and data through our evidence system and list the points where modeling could change time, cost, risk or the chance of success.

You getAn opportunity map, ranked by impact and effort
02

Choose the model-informed strategy

For the opportunities worth taking, we define the question of interest and context of use, draft the ICH M15 assessment, sequence the work against the clinical plan and set out the regulatory interactions.

You getA model-informed strategy and regulatory interaction plan. Steps 1 and 2 form the Program Scan: 5 working days, at a fixed fee credited in full toward the work that follows
03

Implement the models

PopPK, exposure-response, PBPK, C-QTc, mechanistic models and trial simulation. The analysis plan is approved before modeling starts; every run is logged, re-executed and quality-controlled.

You getThe models, the report, the M15 assessment table and all code and data, at a fixed price, up to 4 weeks from a clean dataset
04

Prepare the filing and the agency meeting

We write the modeling sections of briefing documents, place the reports in the eCTD, prepare you for FDA and EMA meetings, help you prepare requests to the FDA MIDD Paired Meeting Program and for scientific advice, and join the meeting where useful.

You getAgency questions on our analyses answered at no extra cost

Opportunities at every stage

What a scan typically finds, from candidate selection to life cycle management. Pick a stage.

The packages we run most often →

Faster, documented to submission standard, and priced to compete

Agentic workflows built for pharmacometrics, running on our own servers, take over the time-consuming steps that can be automated: first drafts of datasets to the pharmacometrician's specification, data checks, run management, diagnostic plots, tables and figures. Every modeling choice, interpretation and recommendation is made by a senior pharmacometrician. Every dataset is checked against source, and every reported result is re-run from versioned code and verified before release. That is how we hold the dates and the prices. Where agents help, and where they do not →

Speed
4weeks

At most, from a clean dataset to the report

  • Fixed proposal within 48 hours of the call
  • Program Scan within 5 working days of receiving your documents
  • Replies within one business day
Quality
M15

Every package documented to the ICH M15 framework

  • Analysis plan approved before modeling starts
  • Every reported run re-executed, datasets double-programmed
  • Quality control on every deliverable
Cost
50%

Below a comparable CRO scope, on average

  • Fixed price, paid at two milestones
  • No change orders within scope
  • A delivery date written into the contract

We guarantee the date and the documentation standard, never regulatory acceptance. Methods and verification →

A one-minute narrated film. Drug development has never offered more modeling options, or been harder to navigate. pmxstudio.ai finds where a model could save a program time and money: its proprietary system scans the program against the literature, agency guidance and years of approvals and rejections to find every real chance to accelerate, reduce or improve; it chooses the strategy, with an ICH M15 assessment for each opportunity worth taking; implements the models at a fixed price, in up to four weeks from a clean dataset, with every result verified; and prepares the filing and the agency meeting. Senior-led, fast, and priced to compete. It ends with an invitation to discuss your program.

Senior experts, selected work

Senior pharmacometricians and quantitative clinical pharmacologists from big pharma and leading CROs lead every program. The expert who scopes your program leads it; clinical, biostatistics and regulatory specialists join when the question needs them.

Improve
Phase 3 dose rationale 6 weeks
Oncology · exposure-response

Exposure-response for efficacy and safety, and a dose-justification memo for Project Optimus.

Accelerate
Phase 1b dose projected 6 weeks
Rare disease · population PK

Population PK from SAD/MAD data and the dose rationale for the end-of-Phase-1 meeting.

Reduce
TQT waiver accepted 5 weeks
Cardiac safety · C-QTc

Pre-specified concentration-QTc analysis of pooled Phase 1 data, including the CSR section.

15+
Years of senior experience behind every program
10+
Regulatory submissions supported since 2022, with FDA, EMA and PMDA interactions
30+
Programs since 2022, from peptides and antibodies to ADCs, ASOs and generics

About the team → · News and notes →

Bring us the program, not just the question

A 15-minute call with the pharmacometrician who would lead the work, about where your program is and the next decision. A fixed proposal follows within 48 hours.